Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
Publication
, Journal Article
Gorse, GJ; Baden, LR; Wecker, M; Newman, MJ; Ferrari, G; Weinhold, KJ; Livingston, BD; Villafana, TL; Li, H; Noonan, E; Russell, ND ...
Published in: Vaccine
January 10, 2008
We evaluated EP HIV-1090 vaccine, a DNA plasmid encoding 21 cytotoxic T-lymphocyte (CTL) epitopes of human immunodeficiency virus type 1 (HIV-1) and the pan-DR helper T-lymphocyte epitope (PADRE), in a dose escalation, randomized, double-blinded, placebo-controlled Phase 1 trial. Vaccine, at 0.5, 2.0, or 4.0mg doses, or placebo was injected four times over 6 months. Forty-two healthy, HIV-1-uninfected adults were enrolled. Using an interferon-gamma ELISPOT assay, a response to PADRE was detected in one vaccine recipient. Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Vaccine
DOI
ISSN
0264-410X
Publication Date
January 10, 2008
Volume
26
Issue
2
Start / End Page
215 / 223
Location
Netherlands
Related Subject Headings
- Virology
- Vaccines, DNA
- T-Lymphocytes, Cytotoxic
- Plasmids
- Male
- Leukocytes, Mononuclear
- Interferon-gamma
- Humans
- HIV-1
- HIV Infections
Citation
APA
Chicago
ICMJE
MLA
NLM
Gorse, G. J., Baden, L. R., Wecker, M., Newman, M. J., Ferrari, G., Weinhold, K. J., … HIV Vaccine Trials Network, . (2008). Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine, 26(2), 215–223. https://doi.org/10.1016/j.vaccine.2007.10.061
Gorse, Geoffrey J., Lindsey R. Baden, Margaret Wecker, Mark J. Newman, Guido Ferrari, Kent J. Weinhold, Brian D. Livingston, et al. “Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.” Vaccine 26, no. 2 (January 10, 2008): 215–23. https://doi.org/10.1016/j.vaccine.2007.10.061.
Gorse GJ, Baden LR, Wecker M, Newman MJ, Ferrari G, Weinhold KJ, et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine. 2008 Jan 10;26(2):215–23.
Gorse, Geoffrey J., et al. “Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.” Vaccine, vol. 26, no. 2, Jan. 2008, pp. 215–23. Pubmed, doi:10.1016/j.vaccine.2007.10.061.
Gorse GJ, Baden LR, Wecker M, Newman MJ, Ferrari G, Weinhold KJ, Livingston BD, Villafana TL, Li H, Noonan E, Russell ND, HIV Vaccine Trials Network. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine. 2008 Jan 10;26(2):215–223.
Published In
Vaccine
DOI
ISSN
0264-410X
Publication Date
January 10, 2008
Volume
26
Issue
2
Start / End Page
215 / 223
Location
Netherlands
Related Subject Headings
- Virology
- Vaccines, DNA
- T-Lymphocytes, Cytotoxic
- Plasmids
- Male
- Leukocytes, Mononuclear
- Interferon-gamma
- Humans
- HIV-1
- HIV Infections